SEMAGLUTIDE
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →The most-studied
GLP-1 in research.
Semaglutide is a single-pathway GLP-1 receptor agonist with the deepest research literature in its class. Albumin-binding modifications extend its plasma half-life into the multi-day range, making it the cleanest baseline for designing weekly-cadence research protocols.
Where Tirzepatide and Retatrutide expand the receptor profile, Semaglutide's value is its narrow specificity and its body of citation. If a study needs a known reference compound, this is it.
| Compound | Semaglutide |
|---|---|
| Sequence length | 31 amino acids |
| Molecular mass | 4113.6 Da |
| Modeled half-life | ~7 days (modeled) |
| Mechanism / research class | GLP-1R agonist. |
| Lab handling solvent | 2mL bacteriostatic water for injection (BWI) |
| Resulting concentration | Yields 5mg per 1.0mL |
| Supply format | Semaglutide · 10MG lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
Semaglutide is the deepest-cited single-pathway GLP-1 receptor agonist in metabolic research. The reference STEP-1 trial reported −14.9% mean body-weight reduction at 68 weeks in the published reference study arm - the baseline for any GLP-1 / GIP / GCG comparison.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002. PubMed ↗
GLP-1 receptor agonism amplifies glucose-dependent insulin secretion. Across the SUSTAIN trial program, Semaglutide produced A1C reductions of 1.4–1.8% in T2D research populations.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide. Lancet Diabetes Endocrinol. 2017;5(4):251-260. PubMed ↗
The SELECT cardiovascular outcomes trial reported a 26% relative reduction in major adverse cardiovascular events (MACE) on Semaglutide vs placebo in T2D populations with established CVD over 39.8 months.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. NEJM. 2023;389(24):2221-2232. PubMed ↗
Questions?
We got answers.
Show references
Used in published research.
4.7 / 5
Solid product, fast EU shipping
Ordered SEMAGLUTIDE for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
